Jones D G, Towns C R
Department of Anatomy and Structural Biology, University of Otago, Dunedin, New Zealand.
Hum Reprod. 2006 May;21(5):1113-6. doi: 10.1093/humrep/dei461. Epub 2005 Dec 16.
Embryonic stem (ES) cell research has garnered almost unprecedented attention. Debate over the boundaries of such research is ongoing, and the regulation of the field varies widely between countries. This article identifies and evaluates the four major positions that emanate from current international regulations. ES cell policies may ultimately impact on public health, and hence they must be both rigorous and transparent. We contend that these goals will only be achieved if policy is both ethically consistent and clinically realistic with regard to the ability to achieve therapeutic goals. We conclude that policies allowing the ongoing extraction of stem cells from spare in vitro fertilization embryos and the creation of embryos for research (within set limitations) cope most adequately with the tension between varying views on the moral status of the human embryo and the therapeutic potential inherent within ES cell research.
胚胎干细胞(ES)研究几乎引起了前所未有的关注。关于此类研究界限的争论仍在继续,而且该领域在各国的监管差异很大。本文识别并评估了现行国际法规产生的四大立场。胚胎干细胞政策最终可能会影响公众健康,因此必须严谨且透明。我们认为,只有当政策在伦理上保持一致且在实现治疗目标的能力方面符合临床实际时,这些目标才能实现。我们得出结论,允许从体外受精备用胚胎中持续提取干细胞以及为研究目的创造胚胎(在设定的限制范围内)的政策,最能妥善应对关于人类胚胎道德地位的不同观点与胚胎干细胞研究内在治疗潜力之间的矛盾。